Abstracts tagged "Biomarkers"

Abstract Number: 2521 • 2016 ACR/ARHP Annual Meeting
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Shintaro Hirata¹, Anthony Marotta², Kentaro Hanami¹ and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported…
Abstract Number: 2892 • 2016 ACR/ARHP Annual Meeting
Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: KL-6 is a glycoprotein expressed on and released from type 2 alveolar cells and the measurement of KL-6 in serum was developed by Kohno…
Abstract Number: 123 • 2016 ACR/ARHP Annual Meeting
A Panel of Urinary Biomarkers to Assess Renal Involvement in Latin American Patients with Systemic Lupus Erythematosus
José A. Gómez-Puerta^1,2, Blanca L Ortiz Reyes¹, Tomás Urrego¹, Adriana L Vanegas^2,3, Carlos Horacio Muñoz^3,4, Mauricio Restrepo², Wilmer Rojas-Zuleta², Sofia Arteaga², Luis Alonso Gonzalez⁴ and Gloria Vásquez^1,4, ¹Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia, ²Rheumatology Unit, Universidad de Antioquia, Medellín, Colombia, ³Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁴Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Some previous studies in Caucasian, Asian, and African-american patients have shown promising results for several urinary biomarkers in patients with lupus nephritis (LN). However,…
Abstract Number: 793 • 2016 ACR/ARHP Annual Meeting
Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
Christopher Sjöwall¹, Chelsea Bentow², Mary Ann Aure², Gabriella Lakos², Peter Martis² and Michael Mahler², ¹Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Research and Development, Inova Diagnostics, San Diego, CA
Multi-parametric model development for assessing lupus nephritis and disease activity Christopher Sjӧwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2, Michael Mahler2 1AIR/Rheumatology, Department…
Abstract Number: 1380 • 2016 ACR/ARHP Annual Meeting
Multicenter Prospective Study on the Role of Urinary HER2 As a Lupus Nephritis Biomarker
Patrícia Costa Reis¹, Kelly Maurer², Emily von Scheven³, Kathleen O'Neil⁴, Jon M. Burnham⁵, Laura E. Schanberg⁶, Michelle Petri⁷ and Kathleen E. Sullivan⁸, ¹Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, Indiana University, Indianapolis, IN, ⁵Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ⁶Pediatrics, Duke Medical Center, Durham, NC, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: HER2 (Human Epidermal Growth Factor Receptor 2) is dramatically overexpressed in the glomeruli and in the tubular compartment of patients with lupus nephritis, but…
Abstract Number: 2067 • 2016 ACR/ARHP Annual Meeting
Dermal Fibroblasts from Patients with Lupus Nephritis Express an Anti-Fibrotic Transcriptome
Robert M Clancy¹, Evan Der², Kemal Akat³, Anna R. Broder⁴, H. Michael Belmont⁵, Peter M. Izmirly⁵, Beatrice Goilav⁶, Thomas Tuschl³, Chaim Putterman⁶ and Jill P. Buyon⁷, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Rockefeller University, New York, NY, ⁴Medicine/Rheumatology, Division of Rheumatology, Albert Einstein College of Med, Bronx, NY, ⁵New York University School of Medicine, New York, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁷Medicine, New York University School of Medicine, New York, NY
Background/Purpose: The premise of this study is that the impact of renal injury in lupus nephritis is widespread with consequences to resident cells in other…
Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA study group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…
Abstract Number: 2907 • 2016 ACR/ARHP Annual Meeting
Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Lise Moreer¹, Hilario Nunes¹, Louise Bondeelle¹, Yurdagul Uzunhan¹, Pascale Ghillani-Dalbin², Dominique Valeyre¹, Lucile Musset³ and Makoto Miyara³, ¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose: ILD is a frequent and potentially severe complication of CTDs. The course of ILD can be difficult to predict in this setting. The term…
Abstract Number: 165 • 2016 ACR/ARHP Annual Meeting
The Apparent Diffusion Coefficient As a Quantitative Imaging Biomarker of Therapeutic Response in Enthesitis-Related Arthritis
Timothy Bray¹, Kanimozhi Vendhan¹, Nicola Ambrose², David Atkinson¹, Shonit Punwani¹, Corinne Fisher², Debajit Sen², Yiannis Ioannou² and Margaret Hall-Craggs¹, ¹Centre for Medical Imaging, UCL, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose : Early treatment in enthesitis-related arthritis (ERA) may have a disease-modifying effect with consequently improved outcomes. However, disease activity may be difficult to assess,…
Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Gloria Salazar¹, Masataka Kuwana², Minghua Wu¹, Jun Ying¹, Julio Charles³, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…
Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Yair Molad^1,2, Yonatan Edel^3,4, Yael Pri-Paz Basson⁵, Elisheva Pokroy-Shapira⁶, Shirly Oren⁵, Ariela Dortort⁵ and Vitaly Kliminski^4,7, ¹Rheumatology Unit, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ²Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Department of Medicine C, Beilinson Hospital, Rabib Medical Center, Petach Tikva, Israel, ⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁶Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁷Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…
Abstract Number: 2574 • 2016 ACR/ARHP Annual Meeting
IL-22 As a Biomarker for Erosive Disease in Rheumatoid Arthritis
Jan Leipe, Hendrik Schulze-Koops and Alla Skapenko, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: Consistent with models of experimental arthritis implicating IL-22 – in the development of joint destruction could previously demonstrate that elevated IL-22 serum levels were…
Abstract Number: 2929 • 2016 ACR/ARHP Annual Meeting
The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis
Sarah Salomon¹, Caroline Guignant², Pierre Morel³, Brigitte Gubler⁴, Patrice Fardellone⁵, Jean-Pierre Marolleau⁶ and Vincent Goeb⁷, ¹Rheumatology, University Hospital of Amiens, Amiens, France, ²Immunology Laboratory, University Hospital of Amiens, Amiens, France, ³Hematology, University Hospital of Amiens, Amiens, France, ⁴Immunology, University Hospital of Amiens, Amiens, France, ⁵Department of Rheumatology, Amiens University hospital, Amiens, France, ⁶hematology, University Hospital of Amiens, Amiens, France, ⁷Rheumatology, Amiens University Hospital, Amiens, France
Background/Purpose: In clinical daily practice, the response to biologic drugs is unpredictable in patients with rheumatoid arthritis (RA). Thus, there is a crucial need for…
Abstract Number: 173 • 2016 ACR/ARHP Annual Meeting
S100A8/A9, a Potent Serum and Molecular Imaging Biomarker for Synovial Inflammation and Joint Destruction in Seronegative Experimental Arthritis
Edwin J. W. Geven¹, Martijn H. J. van den Bosch¹, Shahla Abdolahi-Roodsaz¹, Annet W. Sloetjes¹, Sven Hermann², Michael Schäfers², Marije I. Koenders¹, Dirk Föll³, Johannes Roth⁴, Thomas Vogl⁴ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²European Institute for Molecular Imaging, University of Münster, Münster, Germany, ³Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ⁴Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Seronegative joint diseases, including psoriatic arthritis and juvenile idiopathic arthritis, are characterized by the lack of autoantibodies, which are relevant biomarkers for predicting disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].